Zarxio’s Placeholder Name Hints FDA Wants Generic Feel To Biosimilar Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand firms win with FDA requiring a unique name for biosimilars, but adding suffix will likely group filgrastim products together rather than separate them.